SFPM(SZ:002737) Xin Lang Cai Jing·2026-01-16 01:41Group 1 - The core viewpoint of the news is that Kewah Pharmaceutical experienced a decline in stock price and trading volume, with significant changes in financing and margin trading activities [1][2] - As of January 15, Kewah Pharmaceutical's stock price fell by 0.20%, with a trading volume of 39.39 million yuan, and a net financing outflow of 24.22 million yuan [1] - The company's financing balance is 1.41 billion yuan, accounting for 1.62% of its market capitalization, indicating a low level compared to the past year [1] Group 2 - For the fiscal year ending December 31, Kewah Pharmaceutical reported a revenue of 1.684 billion yuan, a year-on-year decrease of 43.24%, and a net profit attributable to shareholders of -33.54 million yuan, a decrease of 105.72% [2] - The company has distributed a total of 4.045 billion yuan in dividends since its A-share listing, with 1.752 billion yuan distributed in the last three years [3] - As of September 30, 2025, Kewah Pharmaceutical had 48,000 shareholders, a decrease of 2.04%, with an average of 12,166 circulating shares per shareholder, an increase of 2.08% [2]